When was EyePoint Pharmaceuticals founded?

EyePoint Pharmaceuticals was founded in 1987.

Where is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is located in Watertown, United States .

Who is the current CEO of EyePoint Pharmaceuticals?

Nancy Lurker is the current CEO of EyePoint Pharmaceuticals.

How many employees does EyePoint Pharmaceuticals have?

EyePoint Pharmaceuticals has 49 employees as of Dec 31, 2018.

When was the latest funding round of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals's latest funding round was on Jan 03, 2021.

What is the annual revenue of EyePoint Pharmaceuticals?

Annual revenue of EyePoint Pharmaceuticals is $41.4M as on Dec 31, 2022.

Where does EyePoint Pharmaceuticals rank among its competitors?

EyePoint Pharmaceuticals ranks 2 amongst 87 active competitors.

Who are the top competitors of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals' top competitors are 4D Molecular Therapeutics, Rezolute and Molecular Partners.

EyePoint Pharmaceuticals - 2025 Company Profile, Funding & Competitors

Company Details

Developer of small molecule-based therapeutics for treating ophthalmic disorders. The company has developed its proprietary technology Durasert which is a miniaturized, injectable, sustained-release drug delivery system for small molecules. The company's lead product candidates are Yutiq for chronic non-infectious uveitis, and EYEP-1901 for wet AMD, diabetic retinopathy, and retinal vein occlusion.

Website
Social
Email ID: @eyepointpharma.com
Phone Number: +1

Key Metrics

Founded Year

1987

Location

Watertown, United States

Stage

Public

Latest Funding Round

Investors

CRG & 4 more

Ranked

2^nd among

Annual Revenue

as on Dec 31, 2022

Employee Count

as on Dec 31, 2018

Similar Companies

4D Molecular Therapeutics &

Exit Details

Public

Legal entities associated with EyePoint Pharmaceuticals

EyePoint Pharmaceuticals is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
		$41.4M (as on Dec 31, 2022)	818	933

Get your free copy of EyePoint Pharmaceuticals's company profile

EyePoint Pharmaceuticals has raised funding over 5 rounds. Its first funding round was on Mar 28, 2018. Its latest funding round was a Post IPO round on Jan 03, 2021 for $15.7M. 1 investor participated in its latest round, which include CRG, , EW Healthcare Partners and Rosalind Advisors.

EyePoint Pharmaceuticals has 5 institutional investors including CRG, and EW Healthcare Partners.

Here is the list of recent funding rounds of EyePoint Pharmaceuticals:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Jan 03, 2021	$15.7M	Post IPO	2327304	8264037	OcuMension
Feb 13, 2019	$60M	Conventional Debt	5280580	6606659	CRG
Oct 02, 2018	$28.9M	Post IPO	3541726	4306302	EW Healthcare Partners, Rosalind Advisors

Access funding benchmarks and valuations. Sign up today!

View details of EyePoint Pharmaceuticals's funding rounds and investors

EyePoint Pharmaceuticals's employee count trend

EyePoint Pharmaceuticals has 49 employees as of Dec 18. The total employee count is 113.0% more than what it was in Dec 17. Here is EyePoint Pharmaceuticals's employee count trend over the years:

Employee count trend for EyePoint Pharmaceuticals

Uncover EyePoint Pharmaceuticals's growth story! Sign up today!

Top competitors of EyePoint Pharmaceuticals include 4D Molecular Therapeutics, Rezolute and Molecular Partners. Here is the list of Top 10 competitors of EyePoint Pharmaceuticals, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Ridgeback Capital Management, Perceptive Advisors听&补尘辫;听	66/100
2nd	EyePoint Pharmaceuticals 1987, Watertown (United States), Public	Developer of small molecule-based therapeutics for treating ophthalmic disorders	-	CRG, 听&补尘辫;听	65/100
3rd	Rezolute 2012, Denver (United States), Public	Biopharmaceutical company developing therapies for metabolic & orphan diseases	-	Bay City Capital, Citadel听&补尘辫;听	61/100
4th	Molecular Partners 2004, Zurich (Switzerland), Public	Developer of therapeutic solutions for treating multiple diseases	$59.9M	EW Healthcare Partners, Johnson & Johnson Innovation 鈥� JJDC听&补尘辫;听	58/100
5th	Aviceda Therapeutics 2018, Cambridge (United States), Series C	Developer of biotherapeutics for glycol-immune diseases	$255M	Omega Funds, Orbimed听&补尘辫;听	58/100
6th	Epicrispr Bio 2018, San Francisco (United States), Series B	Developer of therapeutics for multiple disease	$68M	Ally Bridge Group, Solve FSHD听&补尘辫;听	55/100
7th	Relmada 2007, Blue Bell (United States), Public	Developing novel drug products for the treatment of multiple disease	$13M	Ben Franklin Technology Partners, Olympus Capital Investments听&补尘辫;听	55/100
8th	CureVac 2000, Tubingen (Germany), Public	Developer of mRNA-based therapeutics against cancer and infectious diseases	$975M	Baillie Gifford, GSK听&补尘辫;听	54/100
9th	Sydnexis 2014, Del Mar (United States), Series B	Developer of a therapeutic formulation for treating myopia	$71.5M	RA Capital Management, Longitude Capital听&补尘辫;听	54/100
10th	EyeBio 2021, London (United Kingdom), Acquired	Developer of therapies to treat ophthalmological diseases	$130M	Omega Funds, Bain Capital Life Sciences听&补尘辫;听	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on EyePoint Pharmaceuticals's competitors? Click to see the top ones

EyePoint Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on EyePoint Pharmaceuticals's sector:

Free

Ophthalmology - Sector Report

Edition: February, 2025 (71 Pages)

View

Media has covered EyePoint Pharmaceuticals for a total of 19 events in the last 1 year, 9 of them have been about company updates and 1 about people movement.